

### Discussion

These studies with the isogenic *cagA* negative mutant strain of *H pylori* demonstrate that deletion of the CagA protein does not effect the ability of *H pylori* to induce IL-8 secretion from gastric epithelial cells. The CagA protein is, therefore, not functionally involved in this response but is a marker for strains with pro-inflammatory properties. As all of the wild-type CagA positive strains we have studied to date induce epithelial IL-8 secretion,<sup>9,10</sup> the bacterial factor(s) stimulating this inflammatory response is clearly closely associated with the expression of *cagA*. The function of the CagA protein remains to be determined.

The CagA protein shows considerable size variation in different strains of *H pylori*, ranging from 128 to 150 kDa.<sup>3</sup> Intragenic repeat sequences are the basis of this heterogeneity.<sup>1</sup> Studies with native<sup>4</sup> and recombinant CagA protein<sup>15</sup> have clearly demonstrated the high immunogenicity of this protein both locally and systemically. It is important to consider the role of this antigen specific response in the immunopathogenesis of chronic gastritis.

If the inflammatory epithelial response generated by type I strains is important for bacterial nutrient supply, one bacterial survival strategy may be to avoid immunological recognition of bacterial inflammatory factors and tissue damaging agents such as the cytotoxin. The highly immunogenic CagA protein may therefore be an "immunological decoy" diverting host responses away from these functionally important bacterial factors.

This study was undertaken with financial assistance from the Yorkshire Regional Health Authority. We thank Mrs S Perry for her excellent technical assistance.

- Covacci A, Censini S, Bugnoli M, Petracca R, Burroni D, Macchia G, *et al*. Molecular characterisation of the 128-kDa immunodominant antigen of *Helicobacter pylori* associated with cytotoxicity and duodenal ulcer. *Proc Natl Acad Sci USA* 1993;90:5791-5.
- Tummuru MKR, Cover TL, Blaser MJ. Cloning and expression of a high-molecular-mass major antigen of *Helicobacter pylori*: evidence of linkage to cytotoxin production. *Infect Immun* 1993;61:1799-809.
- Xiang Z, Censini S, Bayeli PF, Telford JL, Figura N, Rappuoli R, *et al*. Analysis of the expression of CagA and VacA virulence factors in 43 strains of *Helicobacter pylori* reveals that clinical isolates can be divided into two major types and that CagA is not necessary for the expression of the vacuolating cytotoxin. *Infect Immun* 1995;63:94-8.
- Crabtree JE, Taylor JD, Wyatt JL, Heatley RV, Shallcross TM, Tompkins DS, *et al*. Mucosal IgA recognition of *Helicobacter pylori* 120 kDa protein, peptic ulceration and gastric pathology. *Lancet* 1991;338:332-5.
- Xiang Z, Bugnoli M, Rappuoli R, Covacci A, Ponzetto A, Crabtree JE. *Helicobacter pylori*: host responses in peptic ulceration. *Lancet* 1993;341:900-1.
- Telford JL, Ghiara P, Dell'Orco M, Comanducci M, Burroni D, Bugnoli M, *et al*. Gene structure of the *Helicobacter pylori* cytotoxin and evidence of its key role in gastric disease. *J Exp Med* 1994;179:1653-8.
- Crabtree JE, Peichl P, Wyatt JL, Stachl U, Lindley IJD. Gastric interleukin-8 and IgA IL-8 autoantibodies in *Helicobacter pylori* infection. *Scand J Immunol* 1993;37:65-70.
- Crabtree JE, Wyatt JL, Trejdosiewicz LK, Peichl P, Nichols PN, Ramsay N, *et al*. Interleukin-8 expression in *Helicobacter pylori* infected, normal, and neoplastic gastroduodenal mucosa. *J Clin Pathol* 1994;47:61-6.
- Crabtree JE, Farmery SM, Lindley IJD, Figura N, Peichl P, Tompkins DS. CagA/cytotoxic strains of *Helicobacter pylori* and interleukin-8 in gastric epithelial cell lines. *J Clin Pathol* 1994;47:945-50.
- Crabtree JE, Covacci A, Farmery SM, Xiang Z, Tompkins DS, Perry S, *et al*. *Helicobacter pylori* induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype. *J Clin Pathol* 1995;48:41-5.
- Ferrero RL, Cussac V, Courcoux P, Labigne A. Construction of isogenic urease-negative mutants of *Helicobacter pylori* by allelic exchange. *J Bacteriol* 1992;174:4212-17.

*J Clin Pathol* 1995;48:969-971

## A practical single sample dry latex agglutination test for *Helicobacter pylori* antibody detection

P D Midolo, J R Lambert, E G Russell, S K Lin

Gastroenterology  
Research Group,  
Morningside Peninsula  
Hospital and  
Department of  
Microbiology Monash  
Medical Centre  
Melbourne,  
Victoria,  
Australia  
P D Midolo  
J R Lambert  
E G Russell  
S K Lin

Correspondence to:  
Mr P D Midolo,  
Department of  
Microbiology,  
Monash Medical Centre,  
246 Clayton Road,  
Clayton 3168,  
Victoria,  
Australia.

Accepted for publication  
13 March 1995

### Abstract

Assessment of a single serum sample for *Helicobacter pylori* antibodies is frequently requested in routine diagnostic laboratories. Current enzyme linked immunosorbent assay (ELISA) kits are not ideal for testing small numbers of serum samples and some have low sensitivities, specificities or large grey zones. A panel of 90 serum samples from patients who had presented for routine upper endoscopy was used to compare three kits for the detection of *H pylori* antibodies: (1) Pyloriset Dry, total antibody latex agglutination, Orion Diagnostica, Espoo, Finland; (2) Pyloriset enzyme immuno-

assay (EIA), IgG ELISA, Orion; and (3) Hel-p, IgG ELISA, Amrad, Kew, Victoria, Australia. Diagnosis of *H pylori* positivity was made if culture results and either rapid urease test or histopathology were positive. The sensitivity, specificity, positive, and negative predictive value for each test was as follows: Orion: latex 93.3%, 95.6%, 95.5%, 93.3%, respectively; Orion: EIA-G 84.4%, 97.8%, 97.4%, 84.4%, respectively; and Amrad: EIA-G 100%, 88.9%, 90%, 100%, respectively. The latex test performed better than the EIAs with respect to sensitivity and specificity.

(*J Clin Pathol* 1995;48:969-971)

Keywords: *Helicobacter pylori*, serology, diagnostic test.

Table 1 Clinical profile of studied subjects

Clinical details	H pylori positive*	H pylori negative
No. of subjects	45	45
Mean age in years (range)	50.7 ± 2.03 (19-86)	49 ± 2.8 (20-87)
Male : female ratio	25 : 20	14 : 31
Clinical diagnosis		
normal	18	13
oesophagitis	3	10
gastritis	5	14
gastric ulcer	5	0
duodenitis	7	7
duodenal ulcer	7	1

\* *H pylori* positive by culture and at least one other diagnostic test (rapid urease test, histology or urea breath test).

Table 2 Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) of test kits

Test kits	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
Orion (dry latex)	93.3	95.6	95.5	93.3
Orion (EIA-G)	84.4	97.8	97.4	84.4
Amrad (EIA-G)	100	88.9	90	100

*Helicobacter pylori* is now established as the cause of type B active chronic gastritis. Methods first described to investigate *H pylori* used endoscopy and biopsy of the gastric antrum. Biopsy samples can be investigated for *H pylori* colonisation by culture,<sup>1</sup> microscopy,<sup>2</sup> or by urease tests to measure pH changes in the presence of urea.<sup>3</sup> Biopsy is invasive and therefore not practical in prolonged follow up or in epidemiological studies.

Non-invasive methods used to diagnose *H pylori* include a breath test<sup>4</sup> and serological tests. Various serological methods have been used including the complement fixation test, the bacterial agglutination test, the passive haemagglutination test, the haemagglutination assay, immunoblot techniques, and enzyme linked immunosorbent assays (ELISAs).<sup>5</sup> All of these techniques have demonstrated a correlation between reactivity and the presence of *H pylori* in the gastric antrum. Thus, serology is a simple and practical tool to assess *H pylori* infection.

The sensitivity and specificity of these serological tests is still under investigation. The preparation of antigen varies with the different techniques and may account for some of the reported differences between assays.<sup>6</sup> ELISA has been the technique of choice in most laboratories because of its speed, low cost, simplicity, and reproducibility. A latex agglutination test has potential advantages over ELISA kits for many laboratories that wish to offer a *H pylori* antibody test for small numbers of serum samples, as single tests can be done without the need for running numerous controls and reference serum samples. This study compares the performance of the Orion Diagnostica Pyloriset dry latex agglutination test (Espoo, Finland) against two conventional enzyme immunoassay (EIA) tests using a panel of serum samples from patients with defined *H pylori* disease status.

## Methods

The assays involved in the comparison were as follows: Amrad Hel-p EIA, Amrad, Kew,

Victoria, Australia; Orion Diagnostica Pyloriset EIA; and Orion Diagnostica Pyloriset total antibody dry latex agglutination test.

Forty five *H pylori* positive and 45 *H pylori* negative serum samples were tested with each assay. Assays were performed over two days and strictly in accordance with the manufacturer's guidelines. Both EIA kits had similar protocols and both took 150 minutes to complete, excluding dilution, dispensing and washing times. The Orion kit had the advantage of being performed at room temperature compared with 37°C for the Amrad kit. The latex test involved diluting each serum 1 in 4 with dilution buffer, pipetting 40 µl of the diluted sample onto the circle of the test card and mixing. The card was then rotated and tilted in a circular motion for three minutes, during which time evidence of agglutination was observed.

Subjects previously presenting for routine upper endoscopy had venous blood collected and stored on ice. Serum was separated within one hour of collection and stored at -20°C. During endoscopy three antral biopsy specimens were obtained for microbiology (phase contrast microscopy and culture), histopathology and rapid urease test.<sup>7</sup> Diagnosis of *H pylori* positivity was made if culture results and one or more of the other tests were positive. Clinical data were recorded on all subjects. Patients were excluded from the study if they were unable to give informed consent, presented an undue risk for endoscopy, had evidence of previous gastric surgery (other than simple oversewing of ulcer), or were on antimicrobial therapy, including bismuth preparations, within the previous three months. The sensitivity, specificity, positive predictive value and negative predictive value were calculated as previously described.<sup>8</sup>

## Results

Clinical details of the patients included in the study are presented in table 1. The mean age was 49.8 years (range 19 to 87 years) and the male : female ratio was 39 : 51. The criteria for assigning a serum as positive or negative was on the basis of the culture result and one other diagnostic test. This was used as the gold standard by which the three serology methods were compared.<sup>7</sup> Table 2 shows the sensitivity, specificity and positive and negative predictive values for these kits.

The Amrad EIA was the only kit to include a "grey zone" in quantitative assays. This result was defined as an optical density (OD) reading between 0.1 (mean positive control OD) and 0.3 (mean positive control OD) and was deemed indeterminate for *H pylori* antibody status. The manufacturer advised that patients returning this result should be examined using an alternative procedure. In this study 19% of our results were equivocal with this kit. To compare the Amrad sensitivities and specificities with the other kits, we used a cut off value of 0.2 times the mean of the positive controls, as described in their instructions for the performance of epidemiological studies. Using this method, of the 17 equivocal results,

two became positive on recalculation and the rest negative.

### Discussion

All three methods performed well on a small but microbiologically defined panel of serum samples. The manufacturers of commercial serology kits must maintain a balance between sensitivity (true positives) and specificity (true negatives). The Amrad EIA kit had excellent sensitivity but had the lowest specificity of the three tests. The Orion EIA had the best specificity but the lowest sensitivity. The Orion dry latex test had the best compromise with very good sensitivity and specificity.

The Orion dry latex total antibody test was simple and quick to perform. Most serum samples gave clear cut results but one serum showed non-specific agglutination. When re-tested with more vigorous mixing this serum was read as negative. The major advantage of the dry latex test is the ability to test an individual serum. Each test card contains three test wells. The card may easily be cut in three to perform one test at a time. This has cost and convenience advantages over the EIA tests in that a full set of positive and negative controls as well as reference serum samples do not have

to be run to test a single serum. However, automated EIA tests are more convenient for running large numbers of samples.

Based on the results of this study, the Orion Pyloriset dry latex total antibody test is recommended for laboratories which receive small numbers of requests for *H pylori* antibody serology.

- 1 Goodwin CS, Blincow EW, Warren JR, Waters TE, Sanderson CR, Easton L. Evaluation of cultural techniques for isolation of *Campylobacter pyloridis* from endoscopic biopsies of gastric mucosa. *J Clin Pathol* 1985;38:1127-31.
- 2 Pinkard KJ, Harrison B, Capstick JA, Medley G, Lambert JR. Detection of *Campylobacter pyloridis* in gastric mucosa by phase contrast microscopy. *J Clin Pathol* 1986;39:112-13.
- 3 Marshall BJ, Warren JR, Francis GJ, Langton SR, Goodwin CS, Blincow ED. Rapid urease test in the management of *Campylobacter pyloridis*-associated gastritis. *Am J Gastroenterol* 1987;82:200-10.
- 4 Marshall BJ, Surveyor IJ. Carbon-14 urea breath test for the diagnosis of *Campylobacter pylori* associated gastritis. *J Nucl Med* 1988;29:11-16.
- 5 Newell DJ, Stacey AR. The serology of *Campylobacter pylori* infections. In: Rathbone BJ, Headley RV, eds. *Campylobacter pylori and gastroduodenal disease*. Oxford: Blackwell Scientific Publications, 1989:74-82.
- 6 Salama SM, Wefuan JN, Shiro-Koulla S, Mbakop A, Tagni-Sartre M, Ndam ECN, et al. Value of whole-cell antigen extracts for serologic detection of *Helicobacter pylori*. *J Clin Microbiol* 1993;31:3331-2.
- 7 Lin SK, Lambert JR, Schembri MA, Nicholson N, Finlay M, Wong C, et al. A comparison of diagnostic tests to determine *Helicobacter pylori* infection. *J Gastroenterol Hepatol* 1992;7:203-9.
- 8 Kramer MS. The reproducibility and validity of diagnostic tests. In: *Clinical epidemiology and biostatistics*. Berlin: Springer-Verlag, 1988:205-13.

## *Corynebacterium aquaticum* septicaemia in a neutropenic patient

C Moore, R Norton

### Abstract

**Corynebacteria are a well recognised cause of sepsis in the immunocompromised patient. *Corynebacterium aquaticum*, however, is rarely seen in the clinical setting, being an environmental organism associated with fresh water. A septicaemic episode caused by this organism in a 74 year old neutropenic woman with an indwelling central venous catheter is reported. It is postulated that the source of the organism was untreated stored rain-water which she used for showering.**

(*J Clin Pathol* 1995;48:971-972)

Keywords: *Corynebacterium aquaticum*, central venous catheter, septicaemia.

In the immunocompromised patient, corynebacteria are often implicated as a cause of sepsis. In particular, *Corynebacterium jeikeium* (CJK) and *Corynebacterium Group D2* are frequently associated with catheter related sepsis and urinary tract infections, respectively.<sup>1,2</sup> *Corynebacterium aquaticum* is an environmental organism associated with fresh water.<sup>3</sup> It has been reported in association with neonatal meningitis and urinary tract infection, septicaemia in an elderly patient with diabetes, and relapsing peritonitis with continuous ambulatory peritoneal dialysis.<sup>3-6</sup> The literature, however, is sparse and virtually confined to patients with some form of immunosuppression. Here, we describe a septicaemic episode caused by this organism in a neutropenic

Division of Clinical Microbiology, Institute of Medical and Veterinary Science, Frome Road, Adelaide, South Australia 5000, Australia  
C Moore  
R Norton

Correspondence to: Dr R Norton.

Accepted for publication 1 June 1995